Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
about
The holo-apoptosome: activation of procaspase-9 and interactions with caspase-3Mechanisms of resistance in castration-resistant prostate cancer (CRPC)Therapeutic targeting of cancers with loss of PTEN function.Targeting PI3K in cancer: impact on tumor cells, their protective stroma, angiogenesis and immunotherapyCyclin-dependent kinase 5 acts as a critical determinant of AKT-dependent proliferation and regulates differential gene expression by the androgen receptor in prostate cancer cellsEnriched protein screening of human bone marrow mesenchymal stromal cell secretions reveals MFAP5 and PENK as novel IL-10 modulators.Alternative splicing promotes tumour aggressiveness and drug resistance in African American prostate cancer.PTEN-deficient tumors depend on AKT2 for maintenance and survival.Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survivalTyrosine kinase BMX phosphorylates phosphotyrosine-primed motif mediating the activation of multiple receptor tyrosine kinasesFour microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitroNanomicellar TGX221 blocks xenograft tumor growth of prostate cancer in nude mice.Elevated PI3K signaling drives multiple breast cancer subtypes.Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.p110δ PI3 kinase pathway: emerging roles in cancer.Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer.LncRNA AK023948 is a positive regulator of AKT.Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors.Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospectsPI-3 kinase p110β: a therapeutic target in advanced prostate cancers.Intracellular signaling of cardiac fibroblasts.PI3King the right partner: unique interactions and signaling by p110β.Molecules in medicine mini-review: isoforms of PI3K in biology and disease.Characterization of a novel p110β-specific inhibitor BL140 that overcomes MDV3100-resistance in castration-resistant prostate cancer cells.P110β Inhibition Reduces Histone H3K4 Di-Methylation in Prostate Cancer.p110α and p110β isoforms of PI3K signaling: are they two sides of the same coin?A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells.Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer.PDK1 controls upstream PI3K expression and PIP3 generation.Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment.Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts.Expression of gangliosides, GD1a, and sialyl paragloboside is regulated by NF-κB-dependent transcriptional control of α2,3-sialyltransferase I, II, and VI in human castration-resistant prostate cancer cells.Human prostate cancer xenografts in lit/lit mice exhibit reduced growth and androgen-independent progression.Both p110α and p110β isoforms of PI3K can modulate the impact of loss-of-function of the PTEN tumour suppressor.ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer.Knockdown of the cochaperone SGTA results in the suppression of androgen and PI3K/Akt signaling and inhibition of prostate cancer cell proliferation.Establishment and characterization of patient-derived xenograft models of gastrointestinal stromal tumor resistant to standard tyrosine kinase inhibitors.Inhibition of PTEN activity aggravates cisplatin-induced acute kidney injury.Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors.TGX-221 inhibits proliferation and induces apoptosis in human glioblastoma cells.
P2860
Q24320222-E21C0B27-1346-4B93-BBA3-027446BF774AQ26774221-0B221B14-F573-44C5-9443-93B51F7314EDQ27852764-F60BF1AE-5CF9-42C4-A2CD-E748060218ADQ29248893-E383799A-B97C-454C-AA11-DD044D55273AQ30654792-1E96594B-52D9-477B-982F-F2F4A9A2C962Q33595061-4444C18A-2CFC-4A87-906C-B87347699BCEQ33871417-98B0EB40-82D6-4D0D-9CA4-F571AFE9B6F6Q34016861-4AB2EA2D-2368-47D1-9B1B-52B73CDF1B97Q34633876-89FA79E0-199A-43AB-B132-BFD63C197347Q34743655-38437DC4-8874-4D42-924F-F73A829F89E5Q35010133-1D21A50D-C74E-4D86-9846-25428D35CE0AQ35224405-F0ABBDB9-CCBD-4C6E-8A6D-57570C74640FQ35640263-852961D7-041B-4987-A8FC-A855100B0071Q36269232-9AFFD17D-8BCC-4D28-8892-D02022EDD59BQ36647928-AF4EFE73-8188-44A4-9A42-1B4433BE7617Q37519616-E6294F01-629A-470D-8805-E632C0CC3E06Q37642607-A3DCD46E-1843-4229-AB90-6D2F99ADA12EQ37886009-464D5DA7-24F8-4AA3-8808-913F97C1CF45Q38212470-23038229-EA8A-4B7F-ABB7-EC17EC1E23F1Q38265574-55E391BA-8B2F-40FA-891D-0F3095B094BAQ38423864-144C01BE-68B5-4D48-8E0B-E743762271B6Q38542387-0D6A9165-6385-4669-8370-B705C48AAB29Q38666875-A4EB5FA6-F0F8-454C-A27E-508755DB876BQ38699761-E66675F3-3E58-4D32-A39E-4E263A367B3AQ38734609-16732921-9502-4834-8147-DBAEA4E726FDQ38934741-6B6FAE96-3B4D-4612-A358-9B5AB23A1121Q38945177-5C8D97D8-F695-44CD-9678-09DB07E8E845Q38965768-47F03F90-A0DA-4F2A-AAAF-9E9831BB94C7Q39119229-E4CEB363-4EE4-453E-B460-CF83A4A00B6AQ39168810-4DE5FFC1-D897-418C-8C11-F9A0030B707CQ39205279-7EA0FEB1-8A39-4B0A-AD6C-046F8664AB5AQ39619019-E68C0C2E-A823-4778-9A58-DA89679AFF2BQ39650181-86EB2EC2-129E-40D4-AC2E-102D87A57BD7Q40726891-0401E0BF-CBFD-45B2-9B7D-84E310167BA7Q41768007-96AA4B69-9FE4-4125-ACFF-9F819156FED9Q42439577-02FB72B0-F262-46FF-913F-E1A1D995A97AQ47140976-F40A7AAB-03DA-4433-B9D2-4533A3A62892Q47160630-4E66F564-8617-4254-B519-77EECE82458BQ47399023-CE012FD3-957C-409B-A29A-5774E681F7ADQ48011922-D4706121-A962-4190-9C71-411AF1E6C7C5
P2860
Phosphoinositide 3-kinase pathway activation in phosphate and tensin homolog (PTEN)-deficient prostate cancer cells is independent of receptor tyrosine kinases and mediated by the p110beta and p110delta catalytic subunits.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phosphoinositide 3-kinase path ...... p110delta catalytic subunits.
@ast
Phosphoinositide 3-kinase path ...... p110delta catalytic subunits.
@en
type
label
Phosphoinositide 3-kinase path ...... p110delta catalytic subunits.
@ast
Phosphoinositide 3-kinase path ...... p110delta catalytic subunits.
@en
prefLabel
Phosphoinositide 3-kinase path ...... p110delta catalytic subunits.
@ast
Phosphoinositide 3-kinase path ...... p110delta catalytic subunits.
@en
P2093
P2860
P356
P1476
Phosphoinositide 3-kinase path ...... p110delta catalytic subunits.
@en
P2093
John M Asara
Steven P Balk
Xinnong Jiang
P2860
P304
14980-14989
P356
10.1074/JBC.M109.085696
P407
P577
2010-03-15T00:00:00Z